Major Shareholder BVF Converts $20M Preferred Stock to Common, Boosting Stake to 43.3% Ahead of Merger
XOMA sits 87% above its 52-week low of $22.29.
Summary
Major shareholder Biotechnology Value Fund converted $20.11 million in preferred stock to common shares at $4.03 each, increasing its stake to 43.3% of XOMA Royalty Corp ahead of its pending acquisition.
Key Events · Ownership and Investor Activity · XOMA
-
Strategic Preferred Stock Conversion
Biotechnology Value Fund (BVF) and its affiliates converted 5,003,000 shares of Series X Preferred Stock into common stock at a conversion price of $4.03 per share, totaling $20.11 million.
-
Significant Increase in Ownership
This conversion boosts BVF's aggregate beneficial ownership to 7,593,303 common shares, representing 43.3% of XOMA Royalty Corp's outstanding stock.
-
Pre-Merger Positioning
The conversion occurred on May 14, 2026, shortly after the announcement of XOMA's acquisition by Ligand Pharmaceuticals for $39.00 per share, indicating a strategic move to consolidate voting power.
-
Waiver of Notice Period
The company waived a 61-day notice requirement, allowing BVF to increase its Series X Beneficial Ownership Limitation to 45% and proceed with the conversion rapidly.
Analysis · XOMA · Life Sciences
Biotechnology Value Fund (BVF) and its affiliates converted $20.11 million worth of Series X Preferred Stock into 5,003,000 common shares at a highly favorable price of $4.03 per share. This strategic move, occurring just before the company's acquisition by Ligand Pharmaceuticals for $39.00 per share, significantly increases BVF's beneficial ownership to 43.3% of XOMA's outstanding common stock. The conversion, which involved waiving a notice period, solidifies BVF's position and voting power, indicating strong conviction in the company's value or the merger's outcome.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XOMA was trading at $41.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $522.2M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.